Chemistry
Testosterone enanthate, or testosterone 17β-heptanoate, is a synthetic androstane steroid and a derivative of testosterone. It is an androgen ester; specifically, it is the C17β enanthate (heptanoate) ester of testosterone. History
Testosterone enanthate was described as early as 1952 and was first introduced for medical use in the United States in 1954 under the brand name Delatestryl. Society and culture
Generic names
Testosterone enanthate is the generic name of the drug and its USAN and BAN. It has also referred to as testosterone heptanoate. Brand names
Testosterone enanthate is marketed primarily under the brand name Delatestryl.It is or has been marketed under a variety of other brand names as well, including, among others:
Andro LA
Andropository
Cypionat
Cypoprime
Depandro
Durathate
Everone
Testocyp
Testostroval
Testrin
Testro LA
Xyosted
pharmaqo labs

Availability
Testosterone enanthate is available in the United States and widely elsewhere throughout the world. Testosterone enanthate (testosterone heptanoate) is often available in concentrations of 200 mg per milliliter of fluid. Legal status
Testosterone enanthate, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act and a schedule IV controlled substance in Canada under the Controlled Drugs and Substances Act. Research
As of October 2017, an auto-injection formulation of testosterone enanthate was in preregistration for the treatment of hypogonadism in the United States. Xyosted
On October 1, 2018, the U.S. Food and Drug Administration (FDA) announced the approval of Xyosted. Xyosted, a product of Antares Pharma, Inc., is a single-use disposable auto-injector that dispenses testosterone enanthate. Xyosted is the first FDA-approved subcutaneous testosterone enanthate product for testosterone replacement therapy in adult males. == References ==
In 1876 surgeon Arthur Davy attributed the symptoms to military foot drill where “over-expanding the chest, caused dilatation of the heart, and so induced irritability".During World War I, Sir Thomas Lewis (who had been a member of staff of the Medical Research Committee) studied many soldiers who had been referred to the Military Heart Hospitals in Hampstead and Colchester with disordered action of the heart or valvular disease of the heart. In 1918 he published a monograph summarizing his findings, which showed that the vast majority did not have structural heart disease, as evidenced by the diagnostic methods available at the time. In it, he reviewed the difference in symptoms between effort syndrome and structural heart disease, examined possible causes of effort syndrome, the diagnosis of structural heart disease in soldiers, its outlook and treatment, and lessons learned by the Army. Since then, a variety of similar or partly similar conditions named above have been described. See also
Shell shock
Combat fatigue
Takotsubo cardiomyopathy
Postural orthostatic tachycardia syndrome
Soldiers Heart (novel)

References


== External links ==